对居住在孟买（旧称： Bombay）的古吉拉特族和马尔瓦迪族人群中CYP2C19活性的评估。

Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay).

作者信息

Panchabhai Tanmay S, Noronha Shaun F, Davis Sanish, Shinde Vishal M, Kshirsagar Nilima A, Gogtay Nithya J

机构信息

Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India.

出版信息

BMC Clin Pharmacol. 2006 Oct 24;6:8. doi: 10.1186/1472-6904-6-8.

DOI:10.1186/1472-6904-6-8

PMID:17062149

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1630702/

Abstract

BACKGROUND

Inherited differences in the metabolism and disposition of drugs, and genetic polymorphisms in the targets of drug therapy (e.g., receptors), can greatly influence efficacy and toxicity of medications. Marked interethnic differences in CYP2C19 (a member of the cytochrome P-450 enzyme superfamily catalyzing phase I drug metabolism) which affects the metabolism of a number of clinically important drugs have been documented. The present study evaluated the activity of CYP2C19 in normal, healthy Gujrati and Marwadi subjects by phenotyping (a western Indian population).

METHODS

All subjects received 20 mg of omeprazole, which was followed by blood collection at 3 hrs to estimate the metabolic ratio of omeprazole to 5-hydroxyomeprazole. The analysis was done by HPLC.

RESULTS

It was seen that 10.36% of this population were poor metabolizers(PM) whereas 89.63% were extensive metabolizers(EM).

CONCLUSION

A genotyping evaluation would better help in identifying population specific genotypes and thus help individualize drug therapy.

摘要

背景

药物代谢和处置方面的遗传差异，以及药物治疗靶点（如受体）的基因多态性，可极大地影响药物的疗效和毒性。已有文献记载，细胞色素P - 450酶超家族成员CYP2C19（催化I相药物代谢）存在显著的种族间差异，该酶影响多种临床重要药物的代谢。本研究通过表型分析（针对印度西部古吉拉特族和马尔瓦迪族人群）评估了正常健康的古吉拉特族和马尔瓦迪族受试者中CYP2C19的活性。